96 related articles for article (PubMed ID: 34274356)
1. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
2. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization.
Wang X; Chen J; Shen Y; Zhang H; Xu Y; Zhang J; Cheng L
Cytokine; 2024 Jul; 179():156620. PubMed ID: 38701735
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
Mendes JT; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
[TBL] [Abstract][Full Text] [Related]
6. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
8. Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.
Wang LL; Tuohy S; Xu KL; Nace A; Yang R; Zheng Y; Burdick JA; Cotsarelis G
Adv Healthc Mater; 2024 May; 13(12):e2303256. PubMed ID: 38207170
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
10. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.
Grisé A; Valere LC; Weinstein D; Sami N
Arch Dermatol Res; 2024 May; 316(6):238. PubMed ID: 38795155
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T; Tanaka Y; Petri MA; Smolen JS; Wallace DJ; Dow ER; Higgs RE; Rocha G; Crowe B; Benschop RJ; Byers NL; Silk ME; de Bono S; Fantini D; Hoffman RW
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33037080
[TBL] [Abstract][Full Text] [Related]
13. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
David P; Hen O; Ben-Shabbat N; Macleod T; Amital H; Watad A; McGonagle DG
RMD Open; 2024 May; 10(2):. PubMed ID: 38796180
[TBL] [Abstract][Full Text] [Related]
14. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis.
Sasakura M; Urakami H; Tachibana K; Ikeda K; Hasui KI; Matsuda Y; Sunagawa K; Ennishi D; Tomida S; Morizane S
Allergol Int; 2024 Apr; 73(2):323-331. PubMed ID: 38350816
[TBL] [Abstract][Full Text] [Related]
15. Complete response of actinic prurigo to oral baricitinib.
Gil-Lianes J; Luque-Luna M; Morgado-Carrasco D
J Dtsch Dermatol Ges; 2024 Jun; 22(6):837-838. PubMed ID: 38613522
[No Abstract] [Full Text] [Related]
16. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
[TBL] [Abstract][Full Text] [Related]
17. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma.
Kwon EK; Choi Y; Sim S; Ye YM; Shin YS; Park HS; Ban GY
J Allergy Clin Immunol; 2024 Apr; 153(4):998-1009.e9. PubMed ID: 38061443
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.
Moreno-Vílchez C; Bonfill-Ortí M; Bauer-Alonso A; Notario J; Figueras-Nart I
J Am Acad Dermatol; 2024 May; 90(5):1059-1061. PubMed ID: 38246562
[No Abstract] [Full Text] [Related]
20. Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation.
Diluvio L; Matteini E; Lambiase S; Cioni A; Gaeta Shumak R; Dattola A; Bianchi L; Campione E
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e478-e480. PubMed ID: 38084867
[No Abstract] [Full Text] [Related]
[Next] [New Search]
